Chemo-radiotherapy as Main Treatment Strategy for Rectal Cancer. Can we Provide a More Precise and Effective Treatment (AMPERE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03619668|
Recruitment Status : Recruiting
First Posted : August 8, 2018
Last Update Posted : August 8, 2018
The purpose of this project is to obtain important information about the tumour and surrounding organs during preoperative chemo-radiotherapy for patients with adenocarcinoma of the rectum. The knowledge generated in this project has the potential to make future radiotherapy treatments (RT) of rectal cancer patients more precise, with less side effects. This could lead the way to make chemo-radiotherapy the main treatment modality and spare a large group of patients from the risk of severe complications after surgery. Specifically, we aim to obtain:
- A characterization of systematic and random changes in position and shape of tumours and surrounding organs during RT.
- A patient-specific pre-treatment characterization of random uncertainties in position and shape of the tumour during radiotherapy. This will be used to create and assess an individual, patient-specific treatment strategy, with the possibility to implement an adaptive RT strategy using the information obtained from the MRI-scans during treatment.
- Information about treatment response and local toxicity from morphological and functional data before, during and after CRT.
|Condition or disease|
|Rectal Cancer Rectal Adenocarcinoma Locally Advanced Malignant Neoplasm|
Patients diagnosed with locally advanced adenocarcinoma of the rectum are treated with concomitant chemo-radiotherapy (CRT), with the aim of reducing local recurrences. Depending on tumor location, this is a pre-operative procedure prior to total mesorectal excision or partial mesorectal excision. The surgery is associated with a high risk of postoperative morbidity, however, especially when combined with CRT. Consequently, recent years have seen an increasing focus on other therapeutic approaches, such as "watch and wait", where the aim is to treat some patients with definitive CRT alone. The success of these new approaches directly relies on the effectiveness of the radiotherapy (RT) treatment and thereby on the level as well as the accuracy of the delivered dose to the tumor.
Standard treatment today is based on a single set of CT- and MRI-scans, which are insufficient to estimate the organ motion during RT. Precise knowledge about the variation in position and shape of the tumor using multiple MRI scans before and during RT will have the potential to make future radiotherapy treatments more precise with less side effects.
The investigators will conduct a prospective study of sequential MRI scans before and during CRT. Patients will be MRI scanned six times in addition to the standard MRI-scan appointments and follow-up. This will provide a total of 9 MRI-scans of each patient; 3 before RT, 3 during RT and 3 during follow up. The information gained from these additional scans will provide a much better understanding of the tumor and organs during RT.
This project's overall focus is to make future RT treatments of rectal cancer patients as precise and efficient as possible. This could contribute to and aid the paradigm shift of making chemo-radiotherapy the main treatment strategy for some rectal cancer patients. This has the potential to spare patients of the severe morbidities associated with surgery, as well as the need for stomas.
|Study Type :||Observational|
|Estimated Enrollment :||24 participants|
|Official Title:||Chemo-radiotherapy as Main Treatment Strategy for Rectal Cancer. Can we Provide a More Precise and Effective Treatment|
|Actual Study Start Date :||June 29, 2018|
|Estimated Primary Completion Date :||June 2020|
|Estimated Study Completion Date :||June 2023|
- Changes in position and shape of tumours and surrounding organs during RT. [ Time Frame: Baseline, 3-4 days, an average of 9 days, an average of 16 days, an average of 22 days, average of 37 days, an average of 1 year, an average of 2 years, an average of 3 years ]Use additional MRI scans before radiotherapy (for random changes) and during radiotherapy (for systematic changes). The gross tumor volume (GTV), clinical target volume (CTV) and organs at risk (OAR) will be delineated separately on CT and all MRI-scans. Using a rigid bony anatomy-based method, the MRI-scans will be registered to the planning CT scan, to allow a comparison of the position and shape variations of the volumes. The information gained will be used to evaluate the relevance of current population based planning target volume (PTV) margins, and, if relevant, provide updated recommendations for treatment margins.
- Patient specific pre-treatment systematic changes in position and shape of CTV during radiotherapy. [ Time Frame: Baseline, 3-4 days, an average of 9 days. ]Will be used to create an individual patient specific CTV-PTV margin.
- Change in treated volume using adaptive radiotherapy [ Time Frame: Baseline, an average of 7 days, an average of 14 days, average of 28 days ]An adaptive CTV-to-PTV margin will be calculated and the impact on the treated volume of PTV and OARs is assessed.
- Change in functional imaging parameters, Ktrans and ADC. [ Time Frame: Baseline, 3-4 days, an average of 9 days, an average of 16 days, an average of 22 days, average of 37 days, an average of 1 year, an average of 2 years, an average of 3 years ]MRI scans providing morphological and functional data before, during and after CRT will provide information about treatment response and local toxicity. The functional data (e.g Ktrans and ADC-value) provided from the diffusion weighted imaging (DWI-) and dynamic contrast enhanced (DCE-) MRI scans will be analysed and compared to the morphological data. The change in functional data will be analysed and compared to RT dose plans. These will subsequently be compared to treatment-related adverse events as assessed by CTCAE v4.0 and patient reported outcome as assessed by LARS score and EORTC quality of life questionnaires (QLQ-C30 and QLQ-CR29).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03619668
|Contact: Dennis T. Arp, Medical Physicst||40758694 ext +firstname.lastname@example.org|
|Contact: Martin S. Nielsen, Ph.D.||97661591 ext +email@example.com|
|Aalborg University Hospital||Recruiting|
|Aalborg, Denmark, 9000|
|Contact: Dennis T. Arp, Medical Physicist 40758694 ext +45 firstname.lastname@example.org|
|Principal Investigator:||Dennis T. Arp, Medical Physicist||Department of Medical Physics, Oncology, Aalborg University Hospital|